Physician profile
Eduard Koman
NPI 1144669268
$5,760.53
in general payments reported to CMS, 2019-2025
24 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $672 · 2021: $1,019 · 2022: $781 · 2023: $1,303 · 2024: $874 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,876.22 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Heartflow, INC. | $484.62 | 2022-2024 | Ffrct |
| Amgen INC. | $406.59 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $352.06 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $347.78 | 2021-2025 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $334.49 | 2019-2025 | |
| Pfizer INC. | $315.41 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $308.61 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $212.68 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $170.96 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.13 | 2019-2025 | Jardiance |
| Avinger INC. | $134.36 | 2023 | Pantheris |
| Philips North America LLC | $131.92 | 2020-2024 | (5044) Mcot |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.13 | 2019-2022 | |
| Atricure, INC. | $105.03 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $78.31 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $75.05 | 2023-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $40.45 | 2021-2023 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $33.43 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $30.39 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $21.66 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alnylam Pharmaceuticals INC. | $20.35 | 2025 | Onpattro |
| Bard Peripheral Vascular, INC. | $15.00 | 2021 | |
| Esperion Therapeutics, INC. | $13.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduard Koman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.